Trial
NCT03847090
Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Allena Pharmaceuticals
Collaborators
—
Condition
Enteric Hyperoxaluria
Intervention
Reloxaliase
Why stopped
Interim Analysis -
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-10